IL-33, inflammation and mucus in COPD: the final FRONTIER?
- PMID: 40659469
- DOI: 10.1183/13993003.00831-2025
IL-33, inflammation and mucus in COPD: the final FRONTIER?
Conflict of interest statement
Conflict of interest: J.D. Chalmers reports grants or contracts from AstraZeneca, Boehringer Ingelheim, Chiesi, Genentech, GlaxoSmithKline, Grifols, Insmed, Pfizer, Sanofi and Zambon, and leadership roles as Chair of European Respiratory Society (ERS) Bronchiectasis Guideline Task Force, Chief Editor of the European Respiratory Journal, and Chair of EMBARC Clinical Research Collaboration. M.B. Long has no potential conflicts of interest to disclose.
Comment on
-
A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4.Eur Respir J. 2025 Jul 14;66(1):2402231. doi: 10.1183/13993003.02231-2024. Print 2025 Jul. Eur Respir J. 2025. PMID: 40154559 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources